Single agent versus combination chemotherapy in recurrent cervical cancer

Area of Science:

• Oncology
• Medical Chemotherapy

Background:

• Cisplatin and ifosfamide are established active agents for recurrent and metastatic cervical cancer.
• The combination chemotherapy regimen bleomycin, ifosfamide, and cisplatin (BIP) has shown promise.

Purpose of the Study:

• To compare the efficacy and safety of the BIP regimen versus cisplatin alone in patients with recurrent and metastatic cervical cancer.

Main Methods:

• A total of 106 patients with recurrent/persistent and metastatic cervical cancer were enrolled.
• Patients received either BIP (n=50) or cisplatin alone (n=56) every 3 weeks for up to 6 courses.
• Response rate and survival were analyzed in 97 evaluable patients.

Main Results:

• The BIP group demonstrated a significantly higher response rate (52.2% vs 29.4%, p < 0.01) compared to cisplatin alone.
• Median survival was 8 months for BIP versus 6 months for cisplatin alone (p = 0.18), a difference that was not statistically significant.
• Chemotherapy responders in both groups had significantly better survival than non-responders.
• Patients with good performance status (ECOG 0-2) and those with extrapelvic disease in the BIP group showed better response rates.
• Toxicity was higher with BIP, including nausea, vomiting, alopecia, myelosuppression, reversible encephalopathy, and renal dysfunction, with two treatment-related deaths.

Conclusions:

• The bleomycin, ifosfamide, and cisplatin combination improved response rates in recurrent and metastatic cervical cancer compared to cisplatin monotherapy.
• While effective in improving response, the BIP regimen did not significantly enhance overall survival and was associated with moderate to high toxicity.
• Further confirmation in a larger, randomized phase III study is warranted to validate these findings.